MedPath

Family Motivational Intervention in Schizophrenia

Not Applicable
Conditions
Cannabis
Schizophrenia
Interventions
Behavioral: Family Motivational Intervention
Registration Number
NCT01167556
Lead Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Brief Summary

Cannabis use by people with schizophrenia is associated with family distress and poor clinical outcomes. Therefore, an Family Motivational Intervention (FMI) was developed to help parents to motivate their child with a diagnoses of recent-onset schizophrenia to reduce cannabis use.

In a single-blind randomised clinical trail with 75 patients with the diagnosis of schizophrenia, parents will be assigned to either FMI or to routine care. Assessments will be conducted at baseline and at a 10- and 22-month follow-up. The study hypothesis is that FMI will be more effective than routine care in reducing (a) cannabis use in patients and (b) distress and sense of burden in parents.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
147
Inclusion Criteria
  • Clinical diagnosis of schizophrenia or psychotic-related disorder
  • Onset of schizophrenia or related disorder within pervious the 10 years
  • Cannabis use at least 2 days per week in the 3 months prior to the assessment
  • Antipsychotic medication in prescribed or indicated
  • At least 10 hours of contact with the parents each week in the last month
Exclusion Criteria

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Family Motivational InterventionFamily Motivational InterventionAn intervention provided to parents consisting of 6 sessions of training in Interactions Skills and 6 sessions training in Motivational Interviewing.
Routine care for parentsFamily Motivational InterventionRoutine care for parents consisting of 2 sessions psycho-education and individual support
Primary Outcome Measures
NameTimeMethod
Cannabis use in patients with a diagnosis of recent-onset schizophrenia22-month follow-up (15 months after the intervention has ended)
Secondary Outcome Measures
NameTimeMethod
Medication adherence in patients with a diagnosis of recent-onset schizophrenia22-month follow-up (15 months after the intervention has ended)
Quality of life in patients with recent-onset schizophrenia22-month follow-up (15 months after the intervention has ended)
Stress in parents due to caring for a child with recent-onset schizophrenia22-month follow-up (15 months after the intervention has ended)
Expressed emotion in parents of patients with recent-onset schizophrenia22-month follow-up (15 months after the intervention has ended)

Trial Locations

Locations (1)

Academic Medical Center

🇳🇱

Amsterdam, North Holland, Netherlands

© Copyright 2025. All Rights Reserved by MedPath